Yarrow Bioscience Inc carries no debt; cash flow comfortably covers obligations.

Yarrow Bioscience Inc has insufficient data to evaluate this check.

Yarrow Bioscience Inc has insufficient data to evaluate this check.

Yarrow Bioscience Inc has insufficient data to evaluate this check.

Yarrow Bioscience Inc has a net cash position, so leverage is healthy.

Yarrow Bioscience Inc carries no debt; interest obligations are fully covered.

Yarrow Bioscience Inc's profit margin has increased (-40.56%) in the last year from -7.95K% to -4.73K%, signaling increasing performance

Yarrow Bioscience Inc has insufficient data to evaluate this check.

Yarrow Bioscience Inc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Yarrow Bioscience Inc's return on equity of -69.57%, is lower than 15.00%, indicating bad performance

Yarrow Bioscience Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Yarrow Bioscience Inc has insufficient public price history to evaluate earnings stability.

Yarrow Bioscience Inc has negative free cash flow, indicating the company is burning cash rather than generating it

Yarrow Bioscience Inc has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Yarrow Bioscience Inc's yearly earnings has increased -33.52% since last year from $-39.83M to $-26.48M, signaling increasing performance

Yarrow Bioscience Inc's yearly revenue has increased 13.77% since last year from $501.00K to $570.00K, signaling increasing performance

ROIC -98.91% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Yarrow Bioscience Inc's 3-year revenue CAGR of 6.12% is positive, indicating growing revenue over the past 3 years

Yarrow Bioscience Inc has insufficient public price history to evaluate revenue consistency.

Yarrow Bioscience Inc has insufficient public price history to evaluate ROE consistency.

Yarrow Bioscience Inc has insufficient data to evaluate this check.

Yarrow Bioscience Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Yarrow Bioscience Inc is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Yarrow Bioscience Inc has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Yarrow Bioscience Inc is overvalued relative to its fair value price of -15.44K based on Earnings Fair Value model

Yarrow Bioscience Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Yarrow Bioscience Inc has a price-to-book ratio of 0.03x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Yarrow Bioscience Inc has a price-to-sales ratio of 1.58x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue